Revenue from Contract with Customer, Excluding Assessed Tax of Kezar Life Sciences, Inc. from 31 Dec 2021 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Kezar Life Sciences, Inc. annual and quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD history and change rate from 31 Dec 2021 to 31 Dec 2024.
  • Kezar Life Sciences, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 30 Sep 2024 was $0, a 100% decline year-over-year.
  • Kezar Life Sciences, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2024 was $0, a 100% decline from 2023.
  • Kezar Life Sciences, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $7,000,000.
  • Kezar Life Sciences, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $0.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)

Kezar Life Sciences, Inc. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $0 -$7,000,000 -100% 01 Jan 2024 31 Dec 2024 10-K 25 Mar 2025 2024 FY
2023 $7,000,000 +$7,000,000 01 Jan 2023 31 Dec 2023 10-K 25 Mar 2025 2024 FY
2022 $0 $0 01 Jan 2022 31 Dec 2022 10-K 25 Mar 2025 2024 FY
2021 $0 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2024 2023 FY

Kezar Life Sciences, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $0 -$7,000,000 -100% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q3 2023 $7,000,000 +$7,000,000 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q3 2022 $0 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.